Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment

Authors

  • Carlos Roncero Vall d’Hebron University Hospital, CIBERSAM, Universidad Autónoma de Barcelona
  • Pablo Vega Sociedad Española de Patología Dual, Instituto de Adicciones
  • Jose Martinez-Raga University of Valencia, University Cardenal Herrera CEU
  • Marta Torrens Hospital del Mar, Universidad Autónoma de Barcelona

DOI:

https://doi.org/10.20882/adicciones.908

Keywords:

parenteral drug use, Spain, opioid, injecting drugs, Hepatitis C virus

Abstract

Editorial.

Author Biographies

Carlos Roncero, Vall d’Hebron University Hospital, CIBERSAM, Universidad Autónoma de Barcelona

Addiction and Dual Diagnosis Unit, Department of Psychiatry, Vall d’Hebron University Hospital - Public Health Agency, Barcelona (ASPB), CIBERSAM. Barcelona, Spain. Department of Psychiatry and Legal Medicine, Universidad Autónoma de Barcelona, Barcelona, Spain

Pablo Vega, Sociedad Española de Patología Dual, Instituto de Adicciones

Sociedad Española de Patología Dual, Spain. Instituto de Adicciones, Madrid, Spain

Jose Martinez-Raga, University of Valencia, University Cardenal Herrera CEU

Teaching Unit of Psychiatry and Psychological Medicine, University Hospital Doctor Peset & University of Valencia, Valencia, Spain. University Cardenal Herrera CEU, Valencia, Spain

Marta Torrens, Hospital del Mar, Universidad Autónoma de Barcelona

Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain. IMIM- Hospital del Mar Medical Research Institut, Barcelona, Spain. Department of Psychiatry and Legal Medicine, Universidad Autónoma de Barcelona, Barcelona, Spain

References

Donmall, M., Jones, A., Davies, L. y Barnard, M. (2009). Summary of key findings from the Drug Treatment Outcomes Research Study (DTORS).

EMCDDA. (2016). European Drug Report: Trends and Developments 2016. Luxembourg.

Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., … Dore, G. J. (2015). Recommendations for the management of hepatitis C virus infection among people who inject drugs. The International Journal on Drug Policy, 26, 1028–1038. doi:10.1016/j.drugpo.2015.07.005.

McGowan, C. E. y Fried, M. W. (2012). Barriers to hepatitis C treatment. Liver International : Official Journal of the International Association for the Study of the Liver, 32 Suppl 1, 151–156. doi:10.1111/j.1478-3231.2011.02706.x.

Ministerio de Sanidad Servicios Sociales e igualdad. (2014). 2014 National Report (2013 data) to the EMCDDA. Spain New Development, Trends.

Mravčík, V., Strada, L., Štolfa, J., Bencko, V., Groshkova, T., Reimer, J. y Schulte, B. (2013). Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: A literature review. Patient Preference and Adherence, 7, 1067–1075. doi:10.2147/PPA.S49113.

Muga, R., Zuluaga, P., Sanvisens, A., Rivas, I., Fuster, D., Bolao, F. y Tor, J. (2015). Hepatitis C associated to substance abuse: ever closer to a treatment without Interferon. Adicciones, 27, 141–149.

Roncero, C., Fuste, G., Barral, C., Rodríguez-cintas, L., Martínez-Luna, N., José, E.O. F. y Casas, M. (2011). Therapeutic management and comorbidities in opiate-dependent patients undergoing a replacement therapy programme in Spain: the PROTEUS study. Heroin Addiction and Related Clinical Problems, 13, 5–16.

Rose, V. J., Lutnick, A. y Kral, A. H. (2014). Feasibility of providing interventions for injection drug users in pharmacy settings: a case study among San Francisco pharmacists. Journal of Psychoactive Drugs, 46, 226–232. doi: 10.1080/02791072.2014.921745.

Torrens, M., Fonseca, F., Castillo, C. y Domingo-Salvany, A. (2013). Methadone maintenance treatment in Spain: the success of a harm reduction approach. Bulletin of the World Health Organization, 91, 136–141.

Downloads

Published

2017-04-11

Issue

Vol. 29 No. 2 (2017)

Section

Editorial